Curriculum Vitae

Name: Peter Jeffrey Conn

Work: P. Jeffrey Conn, Ph.D.

Lee E. Limbird Professor of Pharmacology

Director, Vanderbilt Program in Drug Discovery

Department of Pharmacology

Vanderbilt University Medical Center

2220 Pierce Ave.

1215-D Light Hall

Nashville, TN 37232-6600

Phone: 615-***-****

Fax: 615-***-****

E-mail: abph6j@r.postjobfree.com

EDUCATION

1977

- 1981 B.S. Lee University, Cleveland, Tennessee (Psychology) (Magna

Cum Laude

)

1981

- 1982 University of Cincinnati, Cincinnati, Ohio (Physiological

Psychology

)

1982

- 1986 Ph.D. Vanderbilt University, Nashville, Tennessee (Pharmacology)

PROFESSIONAL TRAINING AND EXPERIENCE

1980

- 1981Undergraduate Teaching Assistant, Department of Behavioral and Social

Sciences, Lee University, Cleveland, Tennessee

1981

- 1982Graduate Teaching Assistant, Department of Psychology, University of

Cincinnati, Cincinnati, Ohio

1986

Research Associate, Department of Pharmacology, Vanderbilt University

School of Medicine, Nashville, Tennessee

1986

- 1988Postdoctoral Fellow, Department of Pharmacology, Yale University School of

Medicine, New Haven, Connecticut

1988

Visiting Lecturer, Yale College, Yale University, New Haven, Connecticut

P. Jeffrey Conn Curriculum Vitae Page 2

1988

- 1994Assistant Professor, Department of Pharmacology, Emory University School of

Medicine, Atlanta, Georgia

1994

- 1999Associate Professor, Department of Pharmacology, Emory University School

of Medicine, Atlanta, Georgia

1999

- 2000Professor, Department of Pharmacology, Emory University School of

Medicine, Atlanta, Georgia

2000

- 2003Senior Director and Head, Department of Neuroscience, Merck Research

Laboratories, Merck and Company, West Point, Pennsylvania

2000

- 2005Adjunct Professor, Department of Pharmacology, Emory University School of

Medicine, Atlanta, Georgia

2003

- 2008 Professor, Department of Pharmacology, Vanderbilt University School of

Medicine, Nashville, Tennessee

2003

- presentDirector, Program in Translational Neuropharmacology, Department of

Pharmacology, Vanderbilt University School of Medicine, Nashville, TN.

2004

- presentDirector, Vanderbilt Program in Drug Discovery, Vanderbilt University

School of Medicine, Nashville, TN.

2006

- presentResearch Scientist, VA Medical Center, Nashville, TN

2008

- present Lee E. Limbird Professor of Pharmacology, Department of Pharmacology,

Vanderbilt University School of Medicine, Nashville, Tennessee

CONSULTANCIES AND SCIENTIFIC ADVISORY BOARDS

1986

1988Research Consultant, Miles Pharmaceuticals, New Haven, Connecticut.

Regular weekly visits. Directed research of two full-time laboratory

technicians.

1994

- 1999Research Consultant, Wyeth Ayerst Pharmaceuticals, Research Division,

Princeton, NJ.

1996

- 1997Research Consultant, CNS Research, Eli Lilly and Co, Indianapolis, IN

1997

- 2000Research Consultant, Pfizer Pharmaceuticals, Groton, CT.

2003

- 2004Research Consultant, Boston Scientific, Natick, MA

2004

Research Consultant, Merck and Co., West Point, PA

2004

Research Consultant, Solvay Pharmaceuticals, Marietta, GA

2004

- 2006Scientific Advisory Board Member, Research Consultant, Prescient

Neuropharma, Vancouver, BC, Canada

2005

- 2006 Scientific Advisory Panel, Invitrogen Life Technologies, Madison, WI

2005

- 2006Consultant, Renovis Inc., San Francisco, CA

2006

- 2007Consultant, Eli Lilly and Company, Indianapolis, IN

P. Jeffrey Conn Curriculum Vitae Page 3

2006

- 2007External Advisory Network, Invitrogen, Madison, WI

2006

- 2007Consultant, Roche Pharmaceutical Co., Palo Alto, CA

2005

- 2007Scientific Advisory Board Member, Michael J. Fox Foundation, New York,

NY

2004

- 2007Expert Consultant, Compound Selection Committee, Treatment Units for

Research on Neurocognition and Schizophrenia (TURNS)

2007

- 2008CNS Advisory Board Member, Eyeforpharma, London, UK

2006

- 2008Scientific Advisory Board Member, Cephalon, Inc., West Chester, PA

2006

- 2008Scientific Advisory Board Member, AstraZeneca USA, Wilmington, DE

2004

- 2008Scientific Advisory Board Member, Addex Pharmaceuticals, Geneva,

Switzerland

2007

- 2008CNS Target Advisory Board, Forest Research Institute, Jersey City, NJ

2007

- 2008Scientific Advisory Board Member, CNS, Roche, Basel, Switzerland

2007

- 2008Consultant, LEK Consulting, Chicago, IL

2008

Consultant, Merck and Company, West Point, PA

2005

- 2009Scientific Advisory Board Member, Dystonia Medical Research Foundation, San Francisco, CA

2006

- 2009Scientific Advisory Board Member, NeuroOP Inc., Atlanta, GA

2008

- 2009Executive Scientific Advisory Board Member, Michael J. Fox Foundation,

New York, NY

2008

2009 Merck Serono Scientific Advisory Board, Geneva Swizerland

2008

2009Consultant, Genentech., San Francisco, CA

2005

- presentScientific Advisory Board Member, Seaside Therapeutics, Boston, MA

2006

- presentFounding Member, Cure Dystonia Initiative Advisory Council (CDIAC),

Dystonia Medical Research Foundation, Chicago, IL

2004

- presentScientific Advisory Board Member, Michael J. Fox Foundation, New York,

NY

2008

presentConsultant, Millipore Corp., St. Charles, MO

2008

presentScientific Advisory Board Member, Stanley Center for Psychiatric Research,

Broad Institute

(MIT/Harvard), Cambridge MA

Individual Consultant

visits with:

Bristol Myers and Company, Wallingford CT (1987

)

Merrell Dow Research Institute, Cincinnati, OH (1988, 1991

)

ICI Pharmaceuticals Group, Wilmington, DE (1992

)

Pfizer Pharmaceuticals, Groton, CT (1995

)

Zeneca Pharmaceuticals, Wilmington, DE (1995

)

Parke-Davis Pharmaceuticals, Ann Arbor, MI (1993, 1998

)

Novartis Pharmaceuticals, Basel Switzerland (1999

)

AstraZeneca, Worcester, MA (2000

)

Merck Research Labs, San Diego, La Jolla, CA (2000

)

Acadia Pharmaceuticals, San Diego, CA (2003, 2004, 2005

)

Merck Research Labs, West Point, PA (2004, 2008

)

Neurocrine Biosciences, San Diego, CA (2005

)

Serono Pharmaceutical Research Institute, Geneva, Switzerland (2005

)

P. Jeffrey Conn Curriculum Vitae Page 4

Johnson and Johnson, Raritan, NJ (2005

)

Seaside Therapeutics, Boston, MA (2005

)

Eli Lilly and Co

. Indianapolis, IN (1991, 1995, 1999, 2000, 2003, 2004 2006

-2 visits;

2010

)

Roche Palo Alto, Palo Alto, CA (2006

)

Forest Research Institute, Newark, New York, (2006

)

IMS Health, West Lawn, PA (2007

)

Johnson and Johnson, Beerse, Belgium (2007)

Sepracor,

Inc., Marlborough, MA (2007

)

Lundbeck Research USA, Paramus, NJ (2007

)

Otsuka Pharmaceuticals, NJ (2007

)

Prestwick Pharmaceutical Company, Washington, DC (2007

)

Genentech, Inc

., San Francisco, CA (2007

)

Primary Insight, New York, NY (2007

)

The Frankel Group, New York, NY (2008

)

Metastatix, Inc

., Atlanta, GA (2008)

GlaxoSmithKline, Harlow, UK (2007; 2008)

Adolor Corporation, Exton, PA (2008

)

Abbott Laboratories, Abbott Park, IL (2009

)

PureTech, Boston, MA (2009

)

HONORS AND AWARDS

1980 - 1981 Undergraduate Honors Teaching Assistant, Lee University

1981 Who's Who Among Students in American Colleges and Universities

1981 Behavioral and Social Sciences Departmental Award, Lee University

1982 University of Cincinnati Summer Research Fellowship

1984 1986 Eli Lilly Research Fellowship

1986 American College of Neuropsychopharmacology/ Mead Johnson Travel Award

1988 Winter Conference on Brain Research Fellowship Award

1991 Eli Lilly Graduate Training Award

1998 Distinguished Alumnus in Natural Sciences Award, Lee University

1998 Granted membership in American College of Neuropsychopharmacology

1999 Independent Investigator Award, National Alliance for Research on Schizophrenia and

Depression (NARSAD)

2003 ISI Most-Cited Scientists in Pharmacology & Toxicology from 1993 - 2003

2004 NARSAD Essel Investigator; Distinguished Investigator Award, National

Alliance for Research on Schizophrenia and Depression (NARSAD)

2007 ASPET-Astellas Award in Translational Pharmacology

2007 Pharmacia - ASPET Award for Experimental Therapeutics

2007 Charles R. Park Award for Basic Revealing Insights into Physiology and

Pathophysiology

2007 Discovery Lecturer at Vanderbilt University

2008 Lee University Distinguished Alumnus of the Year Award

2008 PhRMA Foundation Award for Excellence in Pharmacology and Toxicology

2008 Lee E. Limbird Endowed Professor of Pharmacology

2009 Emory Distinguished Lecturer in Pharmacology

P. Jeffrey Conn Curriculum Vitae Page 5

2009 Distinguished Guest, Sun Yat-sen University and The South China Center fr

Innovative Pharmaceutics, Guangzhou, China

2010

Guest Speaker, Ralph J. Cazort Heritage Lecture, Meharry Medical College

Nashville, TN.

RESEARCH GRANTS CURRENT

Functions of Metabotropic Glutamate Receptor Subtypes, 8/1/93 - 7/31/09, NIH/NINDS; RO1,

$1,250,000 direct costs current funding period, P. Jeffrey Conn, Principal Investigator.

Regulation of Signaling by mGluR5, 2/15/01 1/31/11, NIH/NIMH, RO1, $1,125,000 direct

costs current funding period; P. Jeffrey Conn, Principal Investigator.

Metabotropic Glutamate Receptors in Basal Ganglia, 12/01/04 11/30/09, NIH/NINDS, RO1,

$1,165,000 direct costs current funding period, P. Jeffrey Conn, Principal Investigator.

Muscarinic receptor activators as novel antipsychotic agents.

12/01/0511/30/10,

NIH/NIMH

R01, $1,250,000 Direct Costs, P. Jeffrey Conn, Principal Investigator.

Functional effects of mGluR potentiators in the CNS. 7/1/06 6/30/11 NIH/NIMH R01,

$1,000,000 Direct Costs, P. Jeffrey Conn, Principal Investigator.

Discovery of novel allosteric modulators of mGluR4 for treatment of Parkinson s disease.

11/1/07 10/30/11, Michael J. Fox Foundation, LEAPS Award, $3,609,000 Direct Costs, P.

Jeffrey Conn, Principal Investigator.

Novel strategies for treatment of Fragile X syndrome.

11/1/07 10/30/10, Seaside Therapeutics,

$4,000,000 Direct Costs, P. Jeffrey Conn, Principal Investigator.

Modulators of Metabotropic Glutamate Receptor Subtype 2 for Cocaine Dependence

01/01/08-

12/31/11, NIH/NIDA R01, Burnham Institute, $1,240,934 Direct Costs, Subcontract

Vanderbilt, $300,000 Direct Costs. Nicolas Cosford, Principal Investigator; P. Jeffrey

Conn, Principal Investigator, Vanderbilt Subcontract.

Selective M1 mAChR allosteric modulators for the treatment of schizophrenia NIH/NIMH,

3/31/08 3/30/13, $1,250,000 Direct Costs. Craig Lindsley, P. Jeffrey Conn, Joint-

Principal Investigators.

Partial antagonists of mGluR5 for treatment of cocaine addiction. NIH/NIDA, 3/31/08

3/30/13, $1,500,000 Direct Costs. Craig Lindsley, P. Jeffrey Conn, Joint-Principal

Investigators.

Vanderbilt Specialized Chemistry Center for Accelerated Probe Development NIH/NIMH, U54,

9/1/08 8/30/14, $22,000,000 Direct Costs, Craig W. Lindsley, Principal Investigator, P.

Jeffrey Conn, Co-PI

P. Jeffrey Conn Curriculum Vitae Page 6

Johnson and Johnson Industry Sponsored Contract VUMC34998, 12/09/08-12/09/11, $3,257,329

Direct Costs, P. Jeffrey Conn, Principal Investigator

M4 Positive Allosteric Modulators for the Treatment of Schizophrenia, 9/01/09 8/30/12,

NIH:

RO1, $1,250,000 direct costs, Carrie Jones, Principal Investigator, P. Jeffrey Conn, Co-

PI

Vanderbilt NCDDDG for Discovery of Novel Treatments of Schizophrenia, 12/01/09 11/30/14

NIH, U01, $1,396,532 Direct Costs, P. Jeffrey Conn, Principal Investigator

Discovery of M1 antagonists for treatment of Fragile X syndrome. 12/1/09 11/30/13,

Seaside

Therapeutics, $5,000,000 Total Costs, P. Jeffrey Conn, Principal Investiator.

RESEARCH GRANTS PENDING

Roles of M1 and M4 mAChR subtypes in striatum-implication in dystonia treatment, 7/01/09

6/30/10, NIH; RO1, $1,250,000 direct costs for proposed funding period, Zixiu Xiang,

Principal Investigator, P. Jeffrey Conn, Co-PI

Functions of Metabotropic glutamate receptor subtypes, 12/01/09 11/30/14, NIH/NINDS

R01,

$1,250,000 Direct Costs, P. Jeffrey Conn, Principal Investigator

Metabotropic glutamate receptors in basal ganglia, 04/01/10 03/31/15, NIH/NINDS, R01,

$1,250,000 Colleen Niswender, Principal Investigator

Regulation of Signaling by mGluR5, 2/01/11 9/31/16, NIH/NIMH, RO1, $1,125,000 direct

costs current funding period; P. Jeffrey Conn, Principal Investigator.

Muscarinic receptor activators as novel antipsychotic agents. 12/01/10 11/30/15,

NIH/NIMH

R01, $1,250,000 Direct Costs, P. Jeffrey Conn, Principal Investigator.

RESEARCH GRANTS - COMPLETED

Protein Kinase C-Induced Modulation of Calcium Channels, 7/1/87 - 11/31/88, N.I.H.

Personal

NRSA Postdoctoral Fellowship, P. Jeffrey Conn, Principal Investigator. Tj

EMC

/P >BDC

0 Tc 0 Tw -3 -1.165 Td

(

Kindling-Induced Changes in Ionic Conductances in Pyramidal Cells of the Piriform Cortex

and

Hippocampus, 1/1/89 - 12/31/89, $25,000 direct costs, Emory University (N.I.H.

Biomedical Research Support Grant), P. Jeffrey Conn, Principal Investigator.

Cellular Mechanisms of Kindling-Induced Epileptogenesis, 1/1/89 - 12/31/90, $10,000/year

direct costs, Pharmaceutical Manufacturers Association Foundation, P. Jeffrey Conn,

Principal Investigator

.

Molecular and Cellular Mechanisms of Kindling-Induced Seizure Activity, 8/31/89 -

8/31/90,

$10,000 direct costs, Emory University Research Committee, P. Jeffrey Conn, Principal

Investigator.

P. Jeffrey Conn Curriculum Vitae Page 7

Changes in Excitatory Amino Acid Neurotransmission Resulting from Kindling-Induced

Epileptogenesis, 7/1/90 - 6/31/92, Epilepsy Foundation of America, P. Jeffrey Conn,

Principal Investigator, Declined.

Cellular Basis of Long-Lasting Changes in Neuronal Excitability. 2/1/90 - 1/31/95,

N.S.F., P.

Jeffrey Conn, Principal Investigator, Declined.

Regulation of Synaptic Inhibition in the Hippocampus by G-Protein-Linked Glutamate

Receptors, 9/1/92 - 8/31/93, $10,000 direct costs, Emory University Research

Committee, P. Jeffrey Conn, Principal Investigator.

Metabotropic Glutamate Receptors and Synaptic Plasticity, 7/1/92 - 6/30/95, $128,000

direct

costs, Council for Tobacco Research, P. Jeffrey Conn, Principal Investigtor.

Cellular Mechanisms of Kindling-Induced Epileptogenesis, 4/1/90-3/31/95, $323,000 direct

costs; N.I.H, R29, P. Jeffrey Conn, Principal Investigator.

Cellular Mechanisms of Kindling-Induced Epileptogenesis, 4/1/95 - 3/31/99, $455,000

direct

costs, N.I.H, RO1, P. Jeffrey Conn, Principal Investigator.

Physiological Roles of Muscarinic Acetylcholine Receptor Subtypes in the Hippocampus,

7/1/95

- 12/31/98, $204,000 direct costs, Council for Tobacco Research, P. Jeffey Conn,

Principal Investigator.

Production and Characterization of Subtype-Specific Antibodies for Metabotropic Glutamate

Receptors. 2/1/96 - 12/31/98, $125,000 direct costs, Wyeth-Ayerst Pharmaceuticals, P.

Jeffrey Conn, Principal Investigator.

Neuromodulatory Roles of Multiple Muscarinic Receptor Subtypes, 2/1/96 - 1/31/01,

$540,000

direct costs, N.I.H, RO1, P. Jeffrey Conn, Principal Investigator.

Regulation of NMDA receptors by Muscarinic ACh Receptors. 9/30/97 - 5/31/01, $547,000

direct costs, N.I.H., RO1, P. Jeffrey Conn, Principal Investigator.

Inhibition of Glutamate Autoreceptor Function as a Novel Strategy for Treatment of

Schizophrenia, 9/15/98 9/14/00, $100,000 direct costs, National Alliance for Resarch

on Schizophrenia and Depression (NARSAD) Independent Investigator Awar, P. Jeffrey

Conn, Principal Investigator.

Regulation of Substantia Nigra Function by GABA-B Receptors. 5/1/00 - 4/31/01. $40,000

direct costs, Tourette Syndrome Association Research Award, P. Jeffrey Conn, Principal

Investigator.

Regulation of Metabotropic Glutamate Receptor Responses by RGS proteins. 2/1/99 -

1/31/01,

$540,000 direct costs, N.I.H. RO1, Julie Saugstad, Principal Investigator.

P. Jeffrey Conn Curriculum Vitae Page 8

Muscarinic Receptor Proteins in Alzheimer s Disease. 8/1/99 - 7/31/03, $1,019,000 direct

costs,

N.I.H. RO1, Allan Levey, Principal Investigator.

Control of glutamate receptor activation. 7/1/98 - 6/31/02, $535,000 direct costs,

N.I.H., R01,

Steven Traynelis, Principal Investigator.

Metabotropic Glutamate Receptor mGluR4 as a Novel Target for Parkinson's Disease

Treatment.

8/1/98 - 7/31/02, $720,000 direct costs, U.S. Army Medical Research and Material

Command, Allan Levey, Principal Investigator.

Zinc-Dependent Apparent Desensitization of NMDA Receptors. 7/1/00 6/30/04.$775,000

direct costs, N.I.H. RO1, Fang Zheng, Principal Investigator

Metabotropic Glutamate Receptors in Basal Ganglia. Project in program Center Grant

entitled

Models of Parkinson s Disease, 9/1/99 - 8/31/04; N.I.H,. $760,000 direct costs for

individual project, P. Jeffrey Conn, Principal Investigator of project 5; Mahlon Delong,

Principal Investigator of center grant.

Educational Grant in Basic Neuroscience

07/01/03 - 06/30/04, $50,000 direct costs, Eli

Lilly

and Company, P. Jeffrey Conn, Principal Investigator.

Development of a High Throughput Assay for allosteric potentiators of mGluR4, 9/30/04

8/31/05, RO3, NIH/NINDS, $50,000 direct costs, P. Jeffrey Conn, Principal Investigator.

Allosteric Potentiators of mGluR5 as a novel approach for the treatment of Schizophrenia,

05/01/04

- 04/30/05, NARSAD, $100,000 direct costs, P. Jeffrey Conn, Principal

Investigator.

Amgen/Vanderbilt Partnership for Drug Discovery. 1/1/05 6/31/06, Amgen, P. Jeffrey

Conn,

Principal Investigator

.

Discovery of allosteric potentiators of mGluR7 as novel antiparkinsonian agents. 8/01/05-

6/30/07, Michael J. Fox Foundation, $200,000 Direct Costs. P. Jeffrey Conn, Principal

Investigator.

Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor.

02/01/06 -

01/31/2007, NIH/NMDH, X01, P. Jeffrey Conn, Principal Investigator (Facilities access

grant).

Allosteric Potentiators of mGluR5 as a novel approach for the treatment of schizophrenia.

9/01/04 8/31/06, Stanley Medical Research Institute, $150,000 direct costs, P. Jeffrey

Conn, Principal Investigator.

An MLSCN for GPCRs, Ion Channels, and Transporters. 3/1/05 2/28/08, NIH/NIMH, U54,

$7,500,000 Direct Costs, David Weaver, P. Jeffrey Conn, Co- Principal Investigators.

mGluR4 potentiators as a Treatment for Parkinson s Disease. 12/01/05 11/30/07,

NIH/NINDS

R21, $250,000 Direct Costs. P. Jeffrey Conn, Principal Investigator.

P. Jeffrey Conn Curriculum Vitae Page 9

A Direct Assay for HTS of Gi/Go-Linked GPCRs: mGluR7 as the Prototype. 9/30/05

9/29/07, NIH/NINDS, R21, $125,000 Direct Costs, Colleen Niswender, Principal

Investigator.

TRAINING GRANTS

Manisha A. Desai, Predoctoral Graduate Training Award, Eli Lilly and Company, 10/1/91 -

9/31/93.

Valerie Boss, NIH NRSA Postdoctoral Training Award, Multiple subtypes of metabotropic

glutamate receptors, 7/1/92 - 6/30/95.

Danny G. Winder, NIH NRSA Predoctoral Graduate Training Award, Regulation of kainate-

evoked currents by mGluRs, 10/1/93 - 9/30/95.

Heather Prince Miller, Predoctoral Graduate Training Award, Pharmaceutical Manufacturers

Research Association Foundation, AMPA receptor subunit expression and phsiology in

kindling, 1/1/94 - 12/31/96.

Dorothy S. Chung, NIH NRSA Predoctoral Graduate Training Award, The role of mGluR1a in

hippocampal interneurons, 9/1/94 - 8/31/96.

Stefania Risso Bradley, NIH NRSA Postdoctoral Training Award, Physiological roles of

mGluR4a in the hippocampus, 6/1/95 - 2/28/99.

Fang Zheng, NIH NRSA Postdoctoral Training Award, Presynaptic roles of group II mGluRs in

hippocampus, 12/1/97 - 11/30/99.

Michael J. Marino, NIH NRSA Postdoctoral Training Award, Physiological roles of the m1

muscarinic receptor, 4/1/97 - 3/31/98

Susan Taylor Rouse, NIH NRSA Postdoctoral Training Award, Muscarinic acetylcholine

receptors in perforant pathways, 10/1/97 - 9/30/00

Sudar Alagarsamy, NIH NRSA Postdoctoral Training Award, Mechanism of NMDA regulation

of mGluR5 function, 9/1/97 - 8/31/00

Thomas A. Macek, NIH NRSA Predoctoral Graduate Training Award, Modulation of mGluR7

function by protein kinase C, 5/1/98 - 4/30/00.

Herve Schaffhauser, National Alliance on Schizophrenia and Depression (NARSAD) Young

Investigator Award, Molecular Aspect of Inhibition of group II metabotropic glutamate

receptors by protein kinase C, 7/1/99 - 6/31/01.

P. Jeffrey Conn

Curriculum Vitae Page 10

Fang Zheng, National Alliance on Schizophrenia and Depression (NARSAD) Young

Investigator Award, Reduction of zinc inhibition of NMDA receptor by tyrosine kinase

as a new strategy for development of antipsychotic agents, 7/1/99 - 6/31/01.

Richard Peavy, NIH NRSA Predoctoral Graduate Training Award, Desensitization of mGluR5 in

astrocytes mediated by PKC, 7/1/99 - 6/31/01.

Michael Marino, National Parkinson s Disease Foundation, Metabotropicglutamate receptors

as

a novel target for prevention of Parkinson s Disease, 6/1/99 - 5/31/0.

Scott Sorensen, NIH NRSA Postdoctoral Training Award, GRK2-mediated regulation of

mGluR5 signaling, 4/1/00 - 3/31/03.

Rodriguez, Alice, NIH NRSA Postdoctoral Training Award, Development of allosteric

potentiators of mGluR4. 9/1/04 8/31/07.

Jones, Carrie, Pharmaceutical Research and Manufacturers Association Postdoctoral

Fellowship,

Allosteric potentiators of mGluR5 as a novel approach to treatment of schizophrenia.

2/01/06

- 10/31/06.

Jones, Carrie, NIH NRSA Postdoctoral Training Award, mGluR5 allosteric potentiators: In

Vivo Characterization, 11/1/06 10/31/08.

Shirey, Jana, NIH NRSA, Graduate Student Training Award, Development and use of novel

allosteric potentiators to study the role of M4 mAChR in modulating hippocampal

neurotransmission

07/01/07-06/30/09

Sheffler, Doug, Pharmaceutical Research and Manufacturers Association Postdoctoral

Fellowship, Regulation of mGluR1 function by positive allosteric modulators

08/01/07

-07/31/09

Brady, Ashley, NRSA, Ruth L. Kirschstein National Research Service Award, Ectopic

activators

of M1 as novel antipsychotic agents

09/01/07-08/31/09

Jones, Paulianda, Pharmaceutical Research and Manufacturers Association Postdoctoral

Fellowship, Activation of group II mGlu receptors by agonists and positive allosteric

modulators 02/01/08-01/31/10.

Digby, Gregory, NIH/NIMH, Allosteric and orthosteric agonists differentially activate M1

ACh

Receptors.

09/01/09-08/31/12.

Rook, Jerri, NIH/NIMH, In Vivo characterization of mGluR5 positive allosteric modulators.

09/01/09

-08/31/12.

GRADUATE STUDENTS

P. Jeffrey Conn Curriculum Vitae Page 11

Manisha A. Desai, Emory Department of Pharmacology Graduate Program,

1988 - 1993;

Currently Patent Attorney, Eli Lilly and Company, Indianapolis, IN.

Danny G. Winder, Emory Neuroscience Graduate Program,

1990 - 1996; Currently Associate

Professor,

Department of Physiology, Vanderbilt University School of Medicine.

Rob W. Gereau, Emory Neuroscience Graduate Program, 1991 - 1995; Currently Chief, Basic

Research Section and Associate Professor, Department of Anesthesiology, Washington

University School of Medicine.

Dorothy S. Chung, Emory Neuroscience Graduate Program, MD/PhD Program,

1992 - 1997;

Currently Neurology Resident, Johns Hopkins University.

Heather Prince Miller, Emory Neuroscience Graduate Program,

1991 - 1997; Currently

Clinical

Research Scientist, Cato Research, Ltd., Durham, NC.

Thomas A. Macek, Emory Molecular Therepeutics and Toxicology Graduate Program, 1994 -

1999; Currently Clinical Director, Clinical Neurosciences, Takeda Pharmaceuticals.

Richard D. Peavy, Emory Molecular Therepeutics and Toxicology Graduate Program, 1995

2001; Currently Scientific Operations Manager, Laboratory of Allergic Dieases,

National Institute of Allergy and Infectious Diseases, .

Hazar Awad Granko, Emory Molecular Therepeutics and Toxicology Graduate Program,

19962001

; Currently Associate Director, Regulatory Affairs, Pearl Therapeutics, Raleigh, NC

Marion Wittmann,

Department of Physiology, University of Tubingen, Tubingen, Germany,

1998

2001, Currently Senior Research Biologist, Merck Research Labotatories, West

Point, PA.

Olga Maltseva-Poisik, Emory University Neuroscience Graduate Program, 1999 2006.;

Currently, Postdoctoral Fellow, Ion Channel Physiology Group, NIEHS/NIH, Research

Triangle Park, NC.

Yelin Chen, Vanderbilt University Neuroscience Graduate Program, 2003 2007;

Currently, Postdoctoral Associate, Picower Institute for Learning and Memory, MIT,

Cambridge, MA.

Mark Grier, present, Vanderbilt University, Department of Pharmacology, 20072009

Sameer Sharma, Vanderbilt University, Department of Pharmacology (Craig Lindsley, co-

mentor), 20072009

;

Currently, Research Assistant, Department of Pharmacology,

Vanderbilt Medical Center

.

Jennifer Edl-Ayala, Vanderbilt University, Department of Pharmacology, 20042009

Jana Shirey, Vanderbilt University, Department of Pharmacology, 2004 - 2010

P. Jeffrey Conn

Curriculum Vitae Page 12

Alexis Hammond, Vanderbilt University, Department of Pharmacology, 2006-present

Kari Johnson, Vanderbilt University, Department of Pharmacology, 2006present

Tom Bridges, Vanderbilt University, Department of Pharmacology (Craig Lindsley, co-

mentor),

2007

present

Evan Lebois, Vanderbilt University, Department of Pharmacology (Craig Lindsley, co-

mentor),

2007

present

Nicole Miller, Vanderbilt University, Department of Pharmacology, 20072010

Shen Yin, Vanderbilt University, Department of Pharmacology, 20092010POSTDOCTORAL

FELLOWS AND RESEARCH FACULTY

Valerie Boss, 1991 -1994; Currently Assistant Professor, Emory University

.

Stefania Risso Bradley, 1994 - 1999; Currently Senior Research Scientist Acadia

Pharmaceuticals, La Jolla, C

Contact this candidate